High-risk HPV testing in the management of atypical glandular cells: A systematic review and meta-analysis

International Journal of Cancer

Volumn 138, Issue 2, 2016, Pages 303-310

  Verdoodt, Freija ^a   Jiang, Xuezhi ^b,c   Williams, Mark ^b   Schnatz, Peter F ^b,c   Arbyn, Marc ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b READING HOSPITAL AND MEDICAL CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

atypical glandular cells; cervical cancer; endometrial cancer; human papillomavirus; meta analysis

Indexed keywords

ADENOCARCINOMA; COMPLICATION; EARLY CANCER DIAGNOSIS; FEMALE; HUMAN; META ANALYSIS; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY;

ADENOCARCINOMA; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84955633508     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29424     Document Type: Review

References (60)

1. Solomon D, Davey D, Kurman R, et al., The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-9.
2. Lundberg GD, National Cancer Institute. The 1988 Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses. JAMA 1989; 262: 931 -934.
3. Schnatz PF, Guile M, O'sullivan DM, et al., Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 2006; 107: 701-8.
4. Katki HA, Schiffman M, Castle PE, et al., Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results. J Low Genit Tract Dis 2013; 17 (5, Suppl 1): S50-S5.
5. Chummun K, Fitzpatrick M, Lenehan P, et al., Diagnostic and therapeutic dilemma associated with atypical glandular cells on liquid-based cervical cytology. Cytopathology 2012; 23: 378-82.
6. Sharpless KE, O'sullivan DM, Schnatz PF., The utility of human papillomavirus testing in the management of atypical glandular cells on cytology. J Low Genit Tract Dis 2009; 13: 72-8.
7. Patel A, Thampy N, Hemming D, et al., A clinical review of borderline glandular cells reported on liquid-based cervical cytology. BJOG 2010; 117: 1051-9.
8. DeSimone CP, Day ME, Tovar MM, et al., Rate of pathology from atypical glandular cell Pap tests classified by the Bethesda 2001 nomenclature. Obstet Gynecol 2006; 107: 1285-91.
9. Arbyn M, Ronco G, Anttila A, et al., Evidence regarding HPV testing in secondary prevention of cervical cancer. Vaccine 2012; 30 (Suppl 5): F88-F99.
10. Arbyn M, Roelens J, Simoens C, et al., Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst Rev 2013; 3: 1-201.
11. Solomon D, Schiffman MA, Tarone B,. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance (ASCUS): baseline results from a randomized trial. J Natl Cancer Inst 2001; 93: 293-9.
12. Wright TC, Jr, Stoler MH, Behrens CM, et al., The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 2012; 206: 46.
13. Jones BA, Novis DA., Follow-up of abnormal gynecologic cytology: a college of American pathologists Q-probes study of 16132 cases from 306 laboratories. Arch Pathol Lab Med 2000; 124: 665-71.
14. Schnatz PF, Surette AM, O'sullivan DM,. Delayed diagnosis after atypical glandular cells on cervical cytology. J Low Genit Tract Dis 2009; 13: 237-43.
15. Namugenyi SB, Balsan MJ, Glick SN, et al., Prevalence and genotype distribution of human papillomavirus in cytology specimens containing atypical glandular cells: a case-control study. J Clin Virol 2013; 58: 432-6.
16. Diaz-Montes TP, Farinola MA, Zahurak ML, et al., Clinical utility of atypical glandular cells (AGC) classification: cytohistologic comparison and relationship to HPV results. Gynecol Oncol 2007; 104: 366-71.
17. Massad LS, Einstein MH, Huh WK, et al., 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013; 17 (5, Suppl 1): S1-S27.
18. Jordan J, Arbyn M, Martin-Hirsch P, et al., European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology 2008; 19: 342-54.
19. Wright TC, Jr, Massad LS, Dunton CJ, et al., 2006 Consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007; 11: 201-22.
20. Dunton CJ., Management of atypical glandular cells and adenocarcinoma in situ. Obstet Gynecol Clin North Am 2008; 35: 623-32.
21. Cox T,. ASCCP practice guidelines: management issues related to quality of the smear. J Low Genit Tract Dis 1997: 1; 100-6.
22. Wright TC, Cox JT, Massad LS, et al., 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287: 2120-9.
23. Arbyn M, Kyrgiou M, Gondry J, et al., Long term outcomes for women treated for cervical precancer. BMJ 2014; 348: f7700.
24. Arbyn M, Simoens C, Goffin F, et al., Treatment of cervical cancer precursors: influence of age, completeness of excision and cone depth on therapeutic failure, and on adverse obstetric outcomes. BJOG 2011; 118: 1274-5.
25. Arbyn M, Kyrgiou M, Simoens C, et al., Peri-natal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: a meta-analysis. BMJ 2008; 337: a1284.
26. Martin-Hirsch PP, Paraskevaidis E, Bryant A, et al., Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2010; 6: CD001318.
27. Kyrgiou M, Arbyn M, Martin-Hirsch P, et al., Preterm birth after treatment for cervical precancer: an issue yet to be resolved. BMJ 2012; 345: e5847.
28. Moss EL, Arbyn M, Dollery E, et al., European federation of colposcopy quality standards delphi consultation. Eur J Obstet Gynecol Reprod Biol 2013; 170: 255-8.
29. Sarian LO, Rabelo-Santos SH, Derchain SFM, et al., Diagnostic and therapeutic challenges in the management of glandular abnormalities of the cervix. Exp Rev Obstet Gynecol 2012; 7: 49-58.
30. Jaworski RC, Pacey NF, Greenberg ML, et al., The histologic diagnosis of adenocarcinoma in situ and related lesions of the cervix uteri. Adenocarcinoma in situ. Cancer 1988; 61: 1171-81.
31. Schorge JO, Rauh-Hain JA., Atypical glandular cells. Clin Obstet Gynecol 2013; 56: 35-43.
32. Castle PE, Fetterman B, Poitras N, et al., Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet Gynecol 2010; 115 (2, Part 1): 243-8.
33. Castle PE, Fetterman B, Thomas CJ, et al., The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol 2010; 116: 76-84.
34. Schnatz PF, Sharpless KE, O'sullivan DM., Use of human papillomavirus testing in the management of atypical glandular cells. J Low Genit Tract Dis 2009; 13: 94-101.
35. Olesen TB, Svahn MF, Faber MT, et al., Prevalence of human papillomavirus in endometrial cancer: a systematic review and meta-analysis. Gynecol Oncol 2014; 134: 206-15.
36. Ronnett BM, Manos M, Ransley JE, et al., Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum Pathol 1999; 30: 816-25.
37. Saqi A, Gupta PK, Erroll M, et al., High-risk human papillomavirus DNA testing: a marker for atypical glandular cells. Diagn Cytopathol 2006; 34: 235-9.
38. Zhao C, Florea A, Austin RM., Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. Arch Pathol Lab Med 2010; 134: 103-8.
39. Derchain SF, Rabelo-Santos SH, Sarian LO, et al., Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. Gynecol Oncol 2004; 95: 618-23.
40. Whiting PF, Rutjes AW, Westwood ME, et al., QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-36.
41. Harbord RM, Deeks JJ, Egger M, et al., A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007; 8: 239-51.
42. Harbord RM, Whiting P,. metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata J 2009; 9: 211-29.
43. Nyaga VN, Arbyn M, Aerts M,. METAPROP: stata module to perform fixed and random effects meta-analysis of proportions. Stat Software Comp 2014; S457781.
44. Nyaga VN, Arbyn M, Aerts M,. Metaprop: a stata command to perform meta-analysis of binomial data. Arch Public Health 2014; 72: 39.
45. Tobias A,. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 1998; 8: 108-10.
46. Monsonego J, Hudgens MG, Zerat L, et al., Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid based cytology in primary cervical cancer screening (the FASE study). Int J Cancer 2011; 129: 691-701.
47. Monsonego J, Bohbot JM, Pollini G, et al., Performance of the Roche AMPLICOR(R) Human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol Oncol 2005; 99: 160-8.
48. Tambouret RH, Misdraji J, Wilbur DC., Longitudinal clinical evaluation of a novel antibody cocktail for detection of high-grade squamous intraepithelial lesions on cervical cytology specimens. Arch Pathol Lab Med 2008; 132: 918-25.
49. Wang QX, Zhang ZY, Wang SZ, et al., Significance for the detection of human papillomavirus DNA in cervical atypical glandular cells. Natl Med J China 2011; 91: 911-4.
50. Chen SF, Yang SF, Chu TY, et al., Which test is a better strategy to determine the outcome of atypical glandular cell-categorized Pap smears? Immunocytochemical p16INK4A expression or human papillomavirus test-a retrospective cohort study. Gynecol Oncol 2005; 99: 578-84.
51. Irvin W, Evans SR, Andersen W, et al., The utility of HPV DNA triage in the management of cytological AGC. Am J Obstet Gynecol 2005; 193: 559-65.
52. de Oliveira ER, Derchain SF, Sarian LO, et al., Prediction of high-grade cervical disease with human papillomavirus detection in women with glandular and squamous cytologic abnormalities. Int J Gynecol Cancer 2006; 16: 1055-62.
53. Fetterman B, Shaber R, Pawlick G, et al., Human Papillomavirus DNA testing in routine clinical practice for prediction of underlying cervical intraepithelial neoplasia 2/3+ at initial evaluation and in follow-up of women with atypical glandular cell Papanicolaou tests. J Low Genit Tract Dis 2006; 10: 178-9.
54. Liao SY, Rodgers WH, Kauderer J, et al., Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. Int J Cancer 2009; 125: 2434-40.
55. Anderson C, White J, Alderson C, et al., Risk of endometrial cancer with a diagnosis of atypical glandular cells on Pap smear. J Low Genit Tract Dis 2012; 16: S-23.
56. Smith JHF,. Bethesda 2001. Cytopathology 2002; 13: 4-10.
57. Castle PE, Sideri M, Jeronimo J, et al., Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007; 197: 356.
58. Arbyn M, Martin-Hirsch P, Wentzensen N,. Human papillomavirus-based triage of women showing a cervical cytology result of borderline or mild dyskaryosis. BJOG 2010; 117: 641-4.
59. Arbyn M, Verdoodt F, Snijders PJF, et al., Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014; 15: 172-83.
60. Krane JF, Lee KR, Sun D, et al., Atypical glandular cells of undetermined significance. Outcome predictions based on human papillomavirus testing. Am J Clin Pathol 2004; 121: 87-92.